This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Stocks to Watch: Global Industries, NetLogic


NEW YORK (TheStreet) -- Global Industries (GLBL) shares were soaring 52% to $7.83 in premarket trading Monday after the oil and gas industry services provider agreed to be bought by Technip, the France-based provider of engineering services to the energy sector, for $8 a share in cash or roughly $937 million.

The $8 a share acquisition price represents a 55% premium to Global Industries' closing share price on Sept. 9.






Semiconductor company Broadcom (BRCM) agreed to buy chipmaker NetLogic Microsystems (NETL) for $3.7 billion, or $50 a share.

NetLogic shares were surging 50.2% to $47.93; Broadcom shares were falling 1.3% to $33.






Citigroup (C) shares were sliding 3% to $25.93 as analysts slashed estimates for U.S. banks' third-quarter profit by an average of about 45%, citing a "challenging" operating environment.

Banks named in the Citigroup report included Morgan Stanley (MS), Goldman Sachs (GS) and JPMorgan (JPM).

Their respective shares were falling 2% to $14.97, 1.2% to $101 and 2.2% to $31.36.






McGraw-Hill (MHP) said Monday it would separate into two companies: McGraw-Hill Markets, which would focus on capital and commodities markets and include ratings agency Standard & Poor's; and McGraw-Hill Education, which will have a focus on education services.

Shares were rising 2.6% to $39.73.






Bank of America (BAC) shares were tumbling 2.6% to $6.80 after a Bloomberg report said that its status as the biggest U.S. lender by assets will likely be lost as CEO Brian Moynihan scales down operations and says being the biggest doesn't matter.






Carol Bartz resigned her seat on the Yahoo! (YHOO) board Friday, according to a published media report.

Shares were down 2.4% to $14.14.






Healthcare and consumer products giant Johnson & Johnson (JNJ) did not succeed in obtaining U.S. clearance for more widespread usage of its arthritis drug Simponi.

Shares were behind by 1.5% to $62.72.

-- Written by Andrea Tse in New York.



>To contact the writer of this article, click here: Andrea Tse.

Related links:


Copyright 2011 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs